IP Library Granted Patent US 12,343,385
Granted Patent B2
US 12,343,385 · App. 17/985,427 · Granted Jul 1, 2025

Hemostat reconstitution methods and devices

Inventor: Yves Delmotte (Neufmaison, BE)
Assignees: Baxter International Inc.; Baxtter Healthcare SA
A61K38/4833A61L24/0031A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,343,385
App. No.
17/985,427
Granted
Jul 1, 2025
Kind
B2
Abstract

A kit and system for use in establishing local hemostasis includes a first and a second syringe. The first syringe is co-loaded with at least one substrate material and at least one hemostatic agent including a membrane separating the substrate material and the hemostatic agent. The second syringe is loaded with a diluent. In an embodiment, the kit or system includes crosslinked gelatin particles and thrombin, and the diluent is saline.

Claims (24)

1. A system for administering a hemostatic material to a patient, the system comprising;

a first syringe co-loaded with at least one substrate material and at least one hemostatic agent including a membrane separating said substrate material and said hemostatic agent; and

a second syringe loaded with a diluent.

2. The system of claim 1 , wherein said at least one substrate material comprises a gelatin.

3. The system of claim 2 , wherein said gelatin comprises a cross-linked gelatin.

4. The system of claim 3 , wherein said cross-linked gelatin comprises gelatin granules.

5. The system of claim 1 , wherein said at least one hemostatic agent comprises thrombin.

6. The system of claim 1 , wherein said diluent comprises sterile water.

7. The system of claim 1 , wherein said diluent comprises saline.

8. The system of claim 7 , wherein said saline comprises 0.9% (w/v) NaCl.

9. The system of claim 1 , wherein said substrate material is pre-swollen.

10. The system of claim 1 , wherein said membrane comprises a dissolvable, fragmentable, or friable material.

11. The system of claim 10 , wherein said dissolvable, fragmentable, or friable material comprises a gelatin.

12. A kit for use in establishing local hemostasis, comprising;

a first syringe co-loaded with at least one substrate material and at least one hemostatic agent including a membrane separating said substrate material and said hemostatic agent; and

a second syringe loaded with a diluent.

13. The kit of claim 12 , wherein said at least one substrate material comprises a gelatin.

14. The kit of claim 13 , wherein said gelatin comprises a cross-linked gelatin.

15. The kit of claim 14 , wherein said cross-linked gelatin comprises gelatin granules.

16. The kit of claim 12 , wherein said at least one hemostatic agent comprises thrombin.

17. The kit of claim 12 , wherein said diluent comprises sterile water.

18. The kit of claim 12 , wherein said diluent comprises saline.

19. The kit of claim 18 , wherein said saline comprises 0.9% (w/v) NaCl.

20. The kit of claim 12 , wherein said substrate material is pre-swollen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2022
From: DELMOTTE, YVES
To: BAXTER R&D EUROPE SPRL
Reel/Frame 061754/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2022
From: BAXTER R&D EUROPE SPRL
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 061754/0462 →
Continuity (2)
Provisional Application 63283781 · Nov 29, 2021
Related Publication 20230165944A1 · Jun 1, 2023
References Cited (35)
US 5364350A · Dittmann · 1994 [cited by examiner]
US 6063061A · Wallace et al. · 2000 [cited by applicant]
US 6066325A · Wallace et al. · 2000 [cited by applicant]
US 6419656B1 · Vetter · 2002 [cited by examiner]
US 6706690B2 · Reich et al. · 2004 [cited by applicant]
US 7320962B2 · Reich et al. · 2008 [cited by applicant]
US 7435425B2 · Qian et al. · 2008 [cited by applicant]
US 7871637B2 · Qian et al. · 2011 [cited by applicant]
US 8092820B2 · Qian et al. · 2012 [cited by applicant]
US 8303981B2 · Wallace et al. · 2012 [cited by applicant]
US 8357378B2 · Wallace et al. · 2013 [cited by applicant]
US 8383141B2 · Qian et al. · 2013 [cited by applicant]
US 8512729B2 · Wallace et al. · 2013 [cited by applicant]
US 8603511B2 · Wallace et al. · 2013 [cited by applicant]
US 8940335B2 · Goessl · 2015 [cited by applicant]
US 9084728B2 · Goessl et al. · 2015 [cited by applicant]
US 9408945B2 · Goessl et al. · 2016 [cited by applicant]
US 9821025B2 · Hedrich et al. · 2017 [cited by applicant]
US 9833541B2 · McCoy et al. · 2017 [cited by applicant]
US 10245348B2 · Goessl et al. · 2019 [cited by applicant]
US 10322170B2 · Gulle et al. · 2019 [cited by applicant]
US 10994045B2 · Goessl et al. · 2021 [cited by applicant]
US 11583610B2 · Scott et al. · 2023 [cited by applicant]
US 20050226916A1 · Cochrum · 2005 [cited by examiner]
US 20080275387A1 · Yeadon · 2008 [cited by examiner]
US 20210001002A1 · Park · 2021 [cited by third party]
US 20230094351A1 · Addison · 2023 [cited by examiner]
EP 2575770 · 2013 [cited by applicant]
EP 2575775 · 2013 [cited by applicant]
EP 2771027 · 2014 [cited by applicant]
EP 2575775B1 · 2018 [cited by third party]
Written Opinion for Application No. PCT/US2022/079740 dated Oct. 13, 2023 (8 pages). [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2022/079740 dated Mar. 27, 2023 (5 pages). [cited by applicant]
International Preliminary Report on Patentability dated Jan. 15, 2024 (6 pages). [cited by applicant]
Lewis et al., 2013, Journal of Investigative Surgery, 26, 141-148 (Lewis). [cited by third party]